• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Postoperative radiotherapy in pIIIA-N2 Non–Small Cell Lung Cancer after resection and chemotherapy

byDavy LauandAlex Chan
June 28, 2021
in Chronic Disease, Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Postoperative radiotherapy for pIIIA-N2 non-small cell lung cancer did not improve disease-free survival or overall survival, but did improve locoregional recurrence-free survival.

Evidence Rating Level: 1 (Excellent)

The use of postoperative radiotherapy (PORT) has been correlated with increased survival for non-small cell lung cancer (NSCLC) patients, particularly the pN2 NSCLC subtype. However, it is unclear if PORT is associated with prolonged survival in pIIIA-N2 NSCLC patients, including patients who receive adjuvant chemotherapy. The current phase 3 randomized controlled trial aimed to determine the effect of PORT on disease-free survival (DFS) for pIIIA-N2 NSCLC patients, after having undergone a complete resection and 4 cycles of adjuvant chemotherapy. This was a single institution study based in China, with 140 patients receiving PORT and 170 patients in the observation group. PORT was done within 6 weeks after the last chemotherapy cycle, and the median follow-up was 46.0 (95% CI 41.9-51.4) months. Overall, no significant difference was found in disease-free survival between the two groups: The median DFS was 22.1 (95% CI 14.8-29.3) months for the PORT group and 18.6 (95% CI 14.3-23.0) months for the observation group. After 3 years, the DFS was 40.5% and 32.7% respectively. Additionally, overall survival was not significantly different between the PORT and observation cohorts (3-year overall survival of 78.3% and 82.8% respectively, hazards ratio 1.02, 95% CI 0.68-1.52, p = 0.93), but the locoregional recurrence-free survival rates were greater in the PORT group (66.5% versus 59.7%, HR 0.71, 95% CI 0.51-0.97, p = 0.03). No adverse events from the radiotherapy were observed. In conclusion, the use of PORT did not improve disease-free survival or overall survival, but was associated with an improvement in locoregional recurrence-free survival.

Click to read the study in JAMA Oncology

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

Trastuzumab deruxtecan leads to longer overall survival than ramucirumab plus paclitaxel in HER2-positive gastric cancer

Tags: lung canceroncology
Previous Post

2 Minute Medicine Rewind June 28, 2021

Next Post

Use of cloth face masks may reduce exercise performance because of discomfort

RelatedReports

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Endocrinology

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

August 28, 2025
One-year of Herceptin preferable to two-year regimen
Endocrinology

Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

August 28, 2025
Quick Take: Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Tria
Gastroenterology

Trastuzumab deruxtecan leads to longer overall survival than ramucirumab plus paclitaxel in HER2-positive gastric cancer

August 27, 2025
USPSTF recommends chemoprevention for women at high risk for breast cancer
Endocrinology

Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

August 26, 2025
Next Post
Female incontinence associated with physical activity

Use of cloth face masks may reduce exercise performance because of discomfort

Bilateral diagonal earlobe creases associated with increased risk of coronary artery disease

Age-related hearing impairment in older adults associated with decreased physical functioning

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

Neoadjuvant chemoradiotherapy plus surgery increases overall survival of patients with advanced esophageal squamous cell carcinoma compared to surgery alone

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Significant body weight reduction with cagrilintide-semaglutide therapy
  • Machine learning models diagnose celiac disease at similar performance levels to pathologists
  • Presymptomatic treatment of spinal muscular atrophy with risdiplam leads to improved functional outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.